Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches
- 1 October 2017
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (10) , 2092-2100
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: Clinical evaluation and analysis of biomarkersJournal of the American Academy of Dermatology, 2013
- Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroidIndian Journal of Dermatology, Venereology and Leprology, 2013
- Systematic review of treatments for Stevens–Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortalityTherapeutic Advances in Drug Safety, 2011
- Granulysin Delivered by Cytotoxic Cells Damages Endoplasmic Reticulum and Activates Caspase-7 in Target CellsThe Journal of Immunology, 2011
- Evaluation of SCORTEN on a Cohort of Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Included in the RegiSCAR StudyJournal of Burn Care & Research, 2011
- Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysisBritish Journal of Dermatology, 2010
- Interleukin-2 and Inflammation Induce Distinct Transcriptional Programs that Promote the Differentiation of Effector Cytolytic T CellsImmunity, 2010
- Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationshipsJournal of Clinical Epidemiology, 2009
- Dexamethasone Pulse Therapy for Stevens-Johnson Syndrome/Toxic Epidermal NecrolysisActa Dermato-Venereologica, 2007
- Treatment of Toxic Epidermal Necrolysis with Cyclosporin A2000